Literature DB >> 31806519

Clinical implication of tumor site in terms of node metastasis for intrahepatic cholangiocarcinoma.

Woohyung Lee1, Chi-Young Jeong2, Jae Yool Jang2, Young Hoon Roh3, Kwan Woo Kim3, Sung Hwa Kang3, Myung Hee Yoon4, Hyung Il Seo4, Jeong-Ik Park5, Bo-Hyun Jung5, Dong Hoon Shin6, Young Il Choi6, Hyung Hwan Moon6, Je Ho Ryu7, Kwangho Yang7, Chang Soo Choi8, Yo-Han Park8, Yang Won Nah9, Ryounggo Kim10, Jonathan Navarro11, Dae-Hoon Han11, Gi Hong Choi11, Chang Moo Kang11, Kyung-Sik Kim11, Soon-Chan Hong12.   

Abstract

BACKGROUND: The clinical implication of lymph node (LN) dissection of intrahepatic cholangiocarcinoma (ICCA) is still controversial, and LN metastasis (LNM) based on tumor site has not been confirmed yet.
METHODS: Patients who underwent curative-intent surgery at 10 tertiary referral centers were identified and divided into peripheral (PP) and near second confluence level tumor (NC) groups on the basis of the distance from the second confluence and oncological outcomes were compared.
RESULTS: Of 179 patients, 121 patients with LND were divided into the NC (n = 89) and PP groups (n = 32) on the basis of 4.5 cm from the second confluence. NC group showed higher LNM rate than PP group (46.1 vs 21.9%, p = 0.016) and NC was a risk factor for LNM (odds ratio: 4.367; 95% confidence interval: 1.234-15.453, p = 0.022). The 5-year overall survival (OS) rate (38.0% vs. 27.8%, p = 0.777) and recurrence-free survival (RFS) rates (22.8% vs. 25.8%, p = 0.742) showed no differences between the PP and NC groups. In the NC group, N1 patients showed worse 5-year OS (12.7% vs 39.0%, p = 0.004) and RFS (8.8% vs 28.6%, p = 0.004) than the N0 patients. In the PP group, discordant results in 5-year OS (48.9% vs. 50.0%, p = 0.462) and RFS (41.3% vs. 0%, p = 0.056) were found between the N0 and N1 patients.
CONCLUSION: The NC group was an independent risk factor for LNM and LNM worsened prognosis in NC group for ICCA. In the PP group, LND should not be omitted because of high LNM rate and insufficient oncologic evidence.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Intrahepatic cholangiocarcinoma; Lymph node metastasis; Tumor site

Mesh:

Year:  2019        PMID: 31806519     DOI: 10.1016/j.ejso.2019.11.511

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  3 in total

1.  Predicting prognosis and evaluating the benefits of adjuvant chemotherapy depending on the tumor location in intrahepatic cholangiocarcinoma: focusing on the involvement of below 2nd bile duct confluence.

Authors:  Hee Ju Sohn; Hongbeom Kim; Jae Ri Kim; Jae Sung Kang; Youngmin Han; Mirang Lee; Hyeong Seok Kim; Wooil Kwon; Suk Kyun Hong; YoungRok Choi; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh; Jin-Young Jang
Journal:  Ann Surg Treat Res       Date:  2022-05-03       Impact factor: 1.766

2.  Evaluation of nodal status in intrahepatic cholangiocarcinoma: a population-based study.

Authors:  Xiaoyuan Chen; Dawei Rong; Long Zhang; Chuangye Ni; Guoyong Han; Yiwei Lu; Xuejiao Chen; Yun Gao; Xuehao Wang
Journal:  Ann Transl Med       Date:  2021-09

3.  Impact of cirrhosis on long-term survival outcomes of patients with intrahepatic cholangiocarcinoma.

Authors:  Jian Wang; Yiwen Qiu; Yi Yang; Shu Shen; Ming Zhi; Bo Zhang; Wentao Wang
Journal:  Cancer Med       Date:  2022-04-12       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.